ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY — Ângelo Maiolino (2020) | RDL Network
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
Mehmet Turgut, Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin
Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G. Martin, Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kim Ki‐Hyun, Gracia Martínez, Min Chang‐Ki,
Thomas G. Martin, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau
Discussion(0)
No comments yet. Be the first to comment.